原发免疫性血小板减少症发生艾曲泊帕治疗相关动脉血栓形成1例并文献复习

A case of immune thrombocytopenia associated with arterial thrombosis treated with Eltrombopag and literature review

原发免疫性血小板减少症(ITP)是一种以外周血的血小板计数减少为主的自身免疫性疾病,病理机制复杂,以出血为主要临床表现,并发血栓事件相对较少。艾曲泊帕是一种促血小板生成素受体激动剂(TPO-RA),可提升复发及难治性ITP患者的血小板计数。本文通过1例艾曲泊帕治疗相关的ITP患者合并动脉血栓形成的临床资料分析,并对相关文献进行复习,以提高对该病的认识。ITP发生艾曲泊帕治疗相关血栓事件罕见,且治疗存在矛盾,及时识别这两种疾病同时存在且采取综合性、个体化治疗措施是成功治疗的关键。

Primary immune thrombocytopenia(ITP) is an autoimmune disease mainly featured by peripheral blood platelet count reduction. Its pathological mechanism is complicated, with hemorrhage as its main clinical manifestation and relatively few concurrent thrombotic events. Eltrombopag is a thrombopoietin receptor agonist(TPO-RA), which can increase the platelet count of patients with relapsed or refractory ITP. In this paper,through the clinical data analysis of a case of ITP patient complicated with arterial thrombosis associated with Eltrombopag treatment, the related literature was reviewed, so as to improve the understanding of the disease.Thrombotic events related to the treatment of Eltrombopag in ITP are rare, and there are contradictions in the treatment. The key to successful treatment is to timely recognize the coexistence of these two diseases and take comprehensive and individualized treatment measures.